Anti-Retroviral Therapy and Resistance to Anti-Retroviral Drugs

摘要: The era of anti-retroviral therapy starts in 1986. Only three years after the now so designated human immunodeficiency virus (HIV) was identified as causative agent acquired immunodeficency syndrome (AIDS), treatment with zidovudine (3’-azido-3’-deoxythymidine, AZT, ZDV), a nucleoside analogue inhibitor viral reverse transcriptase (RT), shown to significantly reduce mortality patients advanced HIV-1 infection, which paralelled by rise CD4+ lymphocyte counts [1]. also appeared confer benefits less infection [2–4]. Initial high hopes for this drug, however, led subsequent disappointment when, extended follow-up, its effects on morbidity and proved be limited duration [5,6].